Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs AVBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: XOMA 4 – 1 AVBP (1 Tie) Matrix Metrics: XOMA 9 – 1 AVBP

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over ArriVent BioPharma, Inc. (AVBP) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas AVBP carries 43.7/100 (HOLD) at $11.98 (N/M Forward P/E, -3620.0% operating margin).

  • Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. AVBP 43.7/100 HOLD) and 0.68β · 37% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile AVBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs AVBP
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
AVBP NASDAQ
ArriVent BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$11.98
-7.92% 1D
Market Cap $676.0M
TTM Revenue $5.0M
Forward P/E N/M
Beta / 30D Vol 1.27β · 128% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.5%), weak momentum, RSI 31
RSI-14: 30.8 · SMA20: $15.02 · SMA50: $20.98

6-Pillar Scorecard Institutional Category Breakdown (XOMA 4 – 1 AVBP)

Columns: Metric · XOMA · AVBP
1. Valuation Multiples XOMA
Forward P/E 21.5x N/M
Trailing P/E 28.2x N/M
PEG Ratio N/M N/M
EV / Revenue 16.1x 112.5x
2. Growth & Scale XOMA
Revenue Growth (YoY) -22.6% +0.0%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M $5.0M
Market Cap $781.8M $676.0M
3. Profitability & Quality XOMA
Gross Margin 99.0% 100.0%
Operating Margin -3.9% -3620.0%
Net Profit Margin 69.6% 0.0%
Return on Equity (ROE) 34.2% -48.7%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA -$153M
Cash Flow Margin 17.1% EBITDA Mgn N/A
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $113M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVBP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 101.5% (100th %ile) 88.5% (6th %ile)
Put/Call OI Skew N/A 0.16x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (9) vs AVBP (1)
Institutional Metric XOMA AVBP Criterion Row Edge
Market Capitalization
Scale
$781.8M $676.0M Larger Scale XOMA
Trailing P/E Ratio
Valuation
28.2x N/M Lower Multiple XOMA
Forward P/E Ratio
Valuation
21.5x N/M Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-22.6% +0.0% Higher Growth AVBP
Operating Margin (TTM)
Profitability
-3.9% -3620.0% Higher Margin XOMA
Net Profit Margin
Profitability
69.6% 0.0% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -48.7% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 2% ($11–$36) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 1.27β · 128% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$49M $5.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev N/M PEG · 112.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) -$153M ($113M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVBP +14.14 pp
XOMA: -3.81% · AVBP: +10.33%
3M Horizon AVBP +22.79 pp
XOMA: +9.34% · AVBP: +32.13%
6M Horizon AVBP +37.2 pp
XOMA: +34.26% · AVBP: +71.46%
1Y Horizon AVBP +46.33 pp
XOMA: +24.6% · AVBP: +70.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs AVBP. Trailing 12-month operating profitability (XOMA -3.9% vs AVBP -3620.0%) and valuation multiples (XOMA 21.5x vs AVBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
AVBP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.0M
Gross Margin100.0%
Op. Margin-3620.0%
ROE / Fwd P/E-48.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVBP BREAKDOWN
102d in phase · OBV ACCUMULATION
Current IV 88.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact AVBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $676.0M market capitalization and -3620.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs AVBP Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over ArriVent BioPharma, Inc. (AVBP) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas AVBP carries 43.7/100 (HOLD) at $11.98 (N/M Forward P/E, -3620.0% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. AVBP 43.7/100 HOLD) and 0.68β · 37% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: XOMA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 34.5); meanwhile AVBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XOMA leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with AVBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -3620.0% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $5.0M for AVBP. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVBP.

XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas AVBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 112.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus AVBP (-48.7% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, AVBP carries 88.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.27β · 128% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.